Kalbe Farma Tbk PT banner

Intrinsic Value

The intrinsic value of Kalbe Farma Tbk PT (LCLA) under the Base Case is 0.0747 EUR per share. Compared with the current market price of 0.0295 EUR, the stock appears Undervalued by 60% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

LCLA Intrinsic Value
€0.0747
Undervaluation 60%
Intrinsic Value
Price €0.0295
Alert me when LCLA is below its intrinsic value
Today €0.0597 · Already reached, the price is 50.6% below it

LCLA is cheaper than usual. This is its cheapest valuation in the past 4 years.

Alternatives to LCLA

Fundamental Analysis

What Kalbe Farma Tbk PT Does

Pharmaceuticals Health Care

PT Kalbe Farma Tbk is one of Indonesia’s largest healthcare companies. It makes and sells prescription medicines, over-the-counter drugs, vitamins, nutritional products, and some medical-related products. Its brands are bought by hospitals, clinics, pharmacies, distributors, and everyday consumers who use its medicines and health supplements at home.

Headquarters
Indonesia ID
Employees
12 895
IPO date
Jul 30, 1991
Read the full company overview
View Company Overview

Kalbe Farma has no economic moat

No Moat Narrow Wide

Kalbe Farma Tbk PT lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.

Read the full moat analysis
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue LCLA Research

Decided on Kalbe Farma? Get an email when LCLA reaches the price you’d buy at. Free with an account.

What is the Intrinsic Value of one LCLA stock?

The intrinsic value for Kalbe Farma Tbk PT (LCLA) under the Base Case is 0.0747 EUR.

Is LCLA stock undervalued or overvalued?

Compared with the current market price of 0.0295 EUR, the stock appears Undervalued by 60% .

How reliable are our estimates? See how past valuations played out
Back to Top